Request Sample
Request Methodology
Description
Global Bispecific Antibody Market Size:
The global bispecific antibody market was valued at US$ 985.3 Mn in 2018 and growing at a CAGR of 34.8% over the forecast period to reach US$ 6,316.2 Mn by 2026 owing to launch of new products in the market in the future years. For instance, there are more than 200 bispecific antibodies products in the clinical trials which will be launched mostly among them in the future years. Increasing investments in research and development of the development of bispecific antibody products and rising prevalence of cancer. According to WHO, around 9.6 people across the globe are responsible for death due to cancer. Presently only two drugs are approved by the U.S.FDA catumaxomab and blinatumomab. Around 30 bispecific antibodies are expected to be launched in the upcoming years that increases the growth of the market. However, limited number of products available in the market and lack of awareness among the patient population restrains the growth of the market.
This report gives a comprehensive outlook on bispecific antibody across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. This report gives historical, current, and future market sizes (US$ Mn) on the basis of type, application, and region. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global bispecific antibody market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global allergy market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global bispecific antibody products.
Increasing investments in R&D drives the growth of the market
A number of pharmaceutical companies are actively involved in research and development of the bispecific antibodies. To launch the products to strengthen their position in the market and expand their product portfolio to offer better services to their patients. Manufacturers are also following various strategies to speed the development process for immediate launch of the products as soon as possible. For instance, In Dec 2016, MedImmune, LLC and Abpro, collaborated to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor.
North America is the leading the global market
North America is leading the global market and is expected to grow with significant CAGR owing to presence of large number of market players involved in the research and development of new products in the category and rising prevalence of cancer coupled with growing mortality rate in the region is anticipated to drive the growth of the market. Moreover, availability of flexible reimbursement policies in the region is the major factor that drives the growth of the market. Europe is projected to grow with significant CAGR over the forecast years owing to increasing funding from the government for the development of bispecific antibodies and availability of favorable reimbursement for the products.
Competition Assessment
Key player’s profiles :
- Ablynx
- Adimab
- Affimed Therapeutics
- Amgen
- AstraZeneca (MedImmune)
- Chugai Pharmaceutical
- Eli Lilly
- EMD Serono
- Emergent BioSolutions
- Genentech
- Genmab
- Immunomedics
- Jounce Therapeutics
- MacroGenics
- Merus
- Neovii Biotech
- NovImmune
- OncoMed Pharmaceuticals
- Pieris
- Regeneron Pharmaceuticals
- Roche
- Sanofi
Key Findings of the Report:
- Global bispecific antibody market expanding at significant CAGR over 2019 to 2026 owing to number of bispecific antibodies in clinical trials and increasing investments by the market players.
- Based on region, North America accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
- Players focusing on innovation of newer products and collaboration strategies to retain market position in global market
Detailed Segmentation
By Type
- IgG Like Molecule
- Non-IgG Like Molecule
By Application
- Oncology
- Autoimmune Disease
- Others
Geography
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2015 – 2019) and Forecast (2020 – 2026)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Location
GEOGRAPHY
